
Tectonic Therapeutic Inc TECX.OQ TECX.O is expected to report resultson May 7 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Tectonic Therapeutic Inc is for a loss of $1.09 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Tectonic Therapeutic Inc is $72.50, above its last closing price of $21.75.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -1.39 | -0.84 | Beat | 39.4 | |
Sep. 30 2024 | -0.82 | -0.82 | -1.20 | Missed | -45.5 |
Jun. 30 2024 | -1.40 | -1.50 | -4.34 | Missed | -189.3 |
Mar. 31 2024 | -4.32 | -4.32 | -1.80 | Beat | 58.3 |
Dec. 31 2023 | -4.95 | -4.04 | -2.40 | Beat | 40.6 |
Sep. 30 2023 | -3.34 | -3.40 | -5.28 | Missed | -55.3 |
Jun. 30 2023 | -2.48 | -0.90 | -4.44 | Missed | -395 |
Mar. 31 2023 | -6.50 | -6.54 | -6.84 | Missed | -4.6 |
This summary was machine generated May 5 at 21:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)